CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 444 enrolled
Drug / intervention
Multivalent +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03313037
NCT03313037Phase 2Completed
CompareCT.gov

A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE

Pfizer·interventional·Posted Oct 18, 2017·Updated Dec 26, 2019

In Brief

A Phase 2 clinical trial evaluating Multivalent, Prevnar 13, and 2 other interventions for Pneumococcal Infections. Completed, enrolled 444 participants across 14 sites.

Detailed Summary

This is a Phase 2, randomized, double-blinded study with a 2-arm parallel design. Healthy adults aged 60 through 64 years of age with no history of pneumococcal vaccination will be randomized equally to receive either a single intramuscular dose of multivalent pneumococcal conjugate vaccine followed 1 month later with a dose of saline or Prevnar 13 followed 1 month later with a dose of PPSV23 (control group).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Infections
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 18, 2017
Enrollment StartOct 10, 2017
Primary CompletionDec 10, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.7 years ago

Interventions

Multivalentbiological

Pneumococcal conjugate vaccine

Prevnar 13biological

Pneumococcal conjugate vaccine

PPSV23biological

Pneumococcal polysaccharide vaccine

Salineother

Placebo